Get the Stockscreener App
2.405
10.59%
-0.285
Pre-market:
2.80
0.395
+16.42%
Sight Sciences Inc stock is traded at $2.405, with a volume of 315.67K.
It is down -10.59% in the last 24 hours and down -12.23% over the past month.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
See More
Previous Close:
$2.69
Open:
$2.68
24h Volume:
315.67K
Relative Volume:
1.22
Market Cap:
$123.46M
Revenue:
$81.06M
Net Income/Loss:
$-55.55M
P/E Ratio:
-2.1096
EPS:
-1.14
Net Cash Flow:
$-47.98M
1W Performance:
-3.41%
1M Performance:
-12.23%
6M Performance:
-65.40%
1Y Performance:
-44.97%
1-Day Range:
$2.40
$2.75
1-Week Range:
$2.25
$2.93
52-Week Range:
$2.17
$8.45
Sight Sciences Inc Stock (SGHT) Company Profile
Name
Sight Sciences Inc
Sector
Industry
Phone
(415) 889-0550
Address
4040 CAMPBELL AVE,, MENLO PARK
Compare SGHT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGHT
Sight Sciences Inc
|
2.405 | 123.46M | 81.06M | -55.55M | -47.98M | -1.14 |
|
ABT
Abbott Laboratories
|
129.89 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.37 | 140.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
363.66 | 138.77B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
92.33 | 118.39B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
67.95 | 39.95B | 5.72B | 4.17B | 259.90M | 6.97 |
Sight Sciences Inc Stock (SGHT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | UBS | Buy |
| Nov-04-24 | Downgrade | Lake Street | Buy → Hold |
| Aug-21-24 | Initiated | Lake Street | Buy |
| Sep-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-12-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-24-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-10-23 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-23 | Upgrade | Stifel | Hold → Buy |
| Oct-04-22 | Initiated | Needham | Hold |
| Jul-26-22 | Initiated | Stifel | Hold |
| Feb-03-22 | Initiated | William Blair | Outperform |
| Jan-07-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Sight Sciences Inc Stock (SGHT) Latest News
Sight sciences EVP Manohar Raheja buys $53,250 in stock - Investing.com India
Sight Sciences’ (SGHT) Hold Rating Reiterated at Needham & Company LLC - Defense World
Piper Sandler Cuts Sight Sciences (NASDAQ:SGHT) Price Target to $3.50 - Defense World
Compared to Estimates, Sight Sciences (SGHT) Q4 Earnings: A Look at Key Metrics - MSN
Lake Street Capital Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Stifel Nicolaus Has Lowered Expectations for Sight Sciences (NASDAQ:SGHT) Stock Price - Defense World
Earnings call transcript: Sight Sciences Q4 2024 results miss forecasts By Investing.com - Investing.com Australia
Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results, Initiates Full Year 2025 Financial Guidance - Vision Monday
Sight Sciences Faces Headwinds in Glaucoma and Dry Eye Markets, Hold Rating Maintained - TipRanks
Sight Sciences’ Earnings Call: Cautious Optimism Amid Challenges - TipRanks
Sight Sciences price target lowered to $3.50 from $5.50 at Piper Sandler - TipRanks
Stifel cuts Sight Sciences price target to $4, maintains Buy rating By Investing.com - Investing.com South Africa
Stifel cuts Sight Sciences price target to $4, maintains Buy rating - Investing.com
Sight Sciences Stock Hits 52-Week Low at $2.27 Amid Market Challenges - Investing.com India
Sight Sciences Stock Hits 52-Week Low at $2.27 Amid Market Challenges By Investing.com - Investing.com South Africa
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2024 Earnings Call Transcript - Insider Monkey
Citigroup Lowers Sight Sciences (NASDAQ:SGHT) Price Target to $3.00 - Defense World
Sight Sciences Reports 2024 Results and 2025 Outlook - TipRanks
Earnings call transcript: Sight Sciences Q4 2024 results miss forecasts - Investing.com India
Sight Sciences Expects 2025 Revenue To Decline By 6% To 12% - Nasdaq
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates - MSN
Sight Sciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sight Sciences Reports 2024 Financial Results and 2025 Outlook - TipRanks
Sight Sciences earnings missed by $0.01, revenue fell short of estimates - Investing.com UK
Sight Sciences Reports Fourth Quarter and Full Year 2024 - GlobeNewswire
SGHTSight Sciences, Inc. Latest Stock News & Market Updates - StockTitan
Breaking Down Sight Sciences: 6 Analysts Share Their Views - Benzinga
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Sight Sciences Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
March 2025 Penny Stocks To Consider For Growth - Simply Wall St
Sight Sciences (SGHT) Projected to Post Earnings on Wednesday - Defense World
Sight Sciences (SGHT) to Release Quarterly Earnings on Wednesday - MarketBeat
Will Sight Sciences, Inc. (SGHT) Report Negative Earnings Next Week? What You Should Know - MSN
Institutional owners may consider drastic measures as Sight Sciences, Inc.'s (NASDAQ:SGHT) recent US$14m drop adds to long-term losses - Simply Wall St
Sight Sciences To Present Clinical Data On OMNI Surgical System At AGS Annual Meeting 2025 - Nasdaq
Sight Sciences stock hits 52-week low at $2.47 amid market challenges - Investing.com Nigeria
Sight Sciences to Present Comprehensive Clinical Data on - GlobeNewswire
Can This Groundbreaking Glaucoma Treatment Transform Patient Care? New Data Reveals 3-Year Outcomes - StockTitan
Sight Sciences stock hits 52-week low at $2.47 amid market challenges By Investing.com - Investing.com South Africa
Critical Contrast: Microbot Medical (NASDAQ:MBOT) vs. Sight Sciences (NASDAQ:SGHT) - Defense World
Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025 - The Manila Times
Can Sight Sciences Maintain Growth Momentum? Q4 Earnings Date Revealed - StockTitan
Analysts Set Sight Sciences, Inc. (NASDAQ:SGHT) Target Price at $4.68 - MarketBeat
Sight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of “Hold” from Analysts - Defense World
Stifel maintains Buy rating and $5 target on Sight Sciences stock - Investing.com Australia
Stifel maintains Buy rating and $5 target on Sight Sciences stock By Investing.com - Investing.com South Africa
Sight sciences CTO David Badawi sells $15,081 in stock - MSN
Sight Sciences stock hits 52-week low at $2.54 amid market challenges - MSN
SG Americas Securities LLC Grows Stake in Sight Sciences, Inc. (NASDAQ:SGHT) - Defense World
Sight Sciences to Present at Citi’s 2025 Unplugged MedTech and Life Sciences Access Day - GlobeNewswire
Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day - The Manila Times
Sight Sciences Inc Stock (SGHT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.40%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):